Supernus Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUPERNUS PHARMS, and when can generic versions of SUPERNUS PHARMS drugs launch?
SUPERNUS PHARMS has five approved drugs.
There are fifty-seven US patents protecting SUPERNUS PHARMS drugs. There is one tentative approval on SUPERNUS PHARMS drugs.
There are ninety-five patent family members on SUPERNUS PHARMS drugs in thirteen countries and two supplementary protection certificates in two countries.
Summary for Supernus Pharms
International Patents: | 95 |
US Patents: | 57 |
Tradenames: | 5 |
Ingredients: | 4 |
NDAs: | 5 |
Drugs and US Patents for Supernus Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-004 | Apr 22, 2020 | DISCN | Yes | No | 8,796,337 | ⤷ Try for Free | ⤷ Try for Free | ||||
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-004 | Aug 16, 2013 | AB1 | RX | Yes | Yes | 8,992,989 | ⤷ Try for Free | Y | ⤷ Try for Free | ||
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-003 | Aug 16, 2013 | AB1 | RX | Yes | No | 9,555,004 | ⤷ Try for Free | Y | ⤷ Try for Free | ||
Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-001 | Oct 19, 2012 | AB | RX | Yes | No | 9,855,278 | ⤷ Try for Free | Y | ⤷ Try for Free | ||
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-001 | Aug 16, 2013 | AB1 | RX | Yes | No | 8,889,191 | ⤷ Try for Free | ⤷ Try for Free | |||
Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-003 | Oct 19, 2012 | AB | RX | Yes | Yes | 10,220,042 | ⤷ Try for Free | ⤷ Try for Free | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Supernus Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | RE39069 | ⤷ Try for Free |
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-002 | Feb 16, 2018 | RE39069 | ⤷ Try for Free |
Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | RE39069 | ⤷ Try for Free |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SUPERNUS PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsules | 25 mg, 50 mg, and 100 mg | ➤ Subscribe | 2014-05-12 |
➤ Subscribe | Extended-release Capsules | 200 mg | ➤ Subscribe | 2014-04-03 |
➤ Subscribe | Extended-release Tablets | 150 mg and 300 mg | ➤ Subscribe | 2013-04-12 |
International Patents for Supernus Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2864088 | ⤷ Try for Free |
Japan | 2017019874 | ⤷ Try for Free |
European Patent Office | 2623099 | ⤷ Try for Free |
Brazil | 112012013487 | ⤷ Try for Free |
Australia | 2019216707 | ⤷ Try for Free |
Japan | 2023009251 | ⤷ Try for Free |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Supernus Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0138441 | SPC/GB95/028 | United Kingdom | ⤷ Try for Free | PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718 |
2317997 | 2190050-1 | Sweden | ⤷ Try for Free | PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.